- Consolidated sales of €45.9 million, -5.3% at constant exchange rates
- Activity impacted by the COVID-19 pandemic: France -2.6%, International -9.6% at constant exchange rates
- Further growth in Novastep's activity: +25.1% at constant exchange rates
Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME plans) ("Amplitude" or the "Group") (Paris:AMPLI), leading French player on the global surgical technology market for lower-limb orthopedics, announces its sales for the first half of its 2020-21 financial year.
Olivier Jallabert, Amplitude Surgical's CEO, commented: "In the first half of our 2020-21 financial year, Amplitude Surgical's activity was impacted, in the second quarter, by the deterioration in the public health situation associated with COVID-19 on the majority of its markets and by the adoption of restrictions on access to operating rooms. As a result, the Group's activity was down by 5.3% at constant exchange rates compared with the previous year. Novastep has continued its development, and now accounts for approximately 13% of Group sales, with growth of almost 25% at constant exchange rates. Despite the COVID-19 impact, the Group is in a solid financial position and intends to seize any external growth opportunities by looking into openings to acquire rival companies or agents
H1 2020-21 sales | 6 months to
| 6 months to
| Change at current
| Change at |
In €k IFRS | ||||
France | 29,615 | 30,404 | -2.6% | -2.6% |
International | 16,295 | 19,429 | -16.1% | -9.6% |
o/w subsidiaries | 12,457 | 14,363 | -13.3% | -4.4% |
o/w distributors | 3,839 | 5,066 | -24.2% | -24.3% |
Total | 45,910 | 49,833 | -7.9% | -5.3% |
Q2 2020-21 sales | 3 months to
| 3 months to
| Change at current
| Change at
|
In €k IFRS | ||||
France | 15,468 | 18,313 | -15.5% | -15.5% |
International | 8,859 | 10,684 | -17.1% | -10.4% |
o/w subsidiaries | 6,938 | 7,549 | -8.1% | 1.3% |
o/w distributors | 1,921 | 3,136 | -38.7% | -38.7% |
Total | 24,327 | 28,997 | -16.1% | -13.7% |
Over the first half of its 2020-21 financial year (from July to December 2020), Amplitude Surgical recorded sales of €45.9 million, down 7.9% in actual terms and 5.3% at constant exchange rates.
- On the French market, Amplitude Surgical recorded a 2.6% fall in H1 sales to €29.6 million, impacted by the second wave of the COVID-19 pandemic in the second quarter of the Group's financial year (October December 2020) and the adoption of restrictions on access to operating rooms from October 2020. France accounted for 64% of total sales;
- The Group's international activity generated sales of €16.3 million, down 16.1% in actual terms and 9.6% at constant exchange rates. The Group's subsidiaries recorded a 13.3% decrease in sales to €12.5 million, subsidiaries' activity notably being impacted by the public health situation associated with COVID-19 in Brazil, Germany and Australia. Activity with distributors also weakened, falling 24.2% to €3.8 million;
- Amplitude Surgical's direct business (French market and international subsidiaries), which accounted for close to 92% of the Group's total sales, slipped 3.1% at constant exchange rates;
- Sales generated by Novastep, innovative solutions for foot and ankle surgery, continued to grow in the first half and totaled €6.1 million (+25.1% at constant exchange rates), driven by the United States (+42.0% at constant exchange rates). Novastep now accounts for approximately 13% of the Group's sales.
Next press release
H1 2020-21 results, on Wednesday March 24, 2021, after market.
About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2020, Amplitude Surgical had a workforce of 436 employees and recorded sales of nearly 88 million euros.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005500/en/
Contacts:
Amplitude Surgical
Dimitri Borchtch
CFO
finances@amplitude-surgical.com
+33 (0)4 75 41 87 41
NewCap
Investor Relations
Mathilde Bohin/Thomas Grojean
amplitude@newcap.eu
+33 (0)1 44 71 94 94
NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 (0)1 44 71 94 98